chr7-138802974-G-A
Variant summary
Our verdict is Likely benign. Variant got -2 ACMG points: 2P and 4B. PM2BP4_Strong
The NM_001085429.2(TMEM213):c.229G>A(p.Val77Ile) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00000558 in 1,613,196 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 14/20 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★).
Frequency
Consequence
NM_001085429.2 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -2 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
TMEM213 | NM_001085429.2 | c.229G>A | p.Val77Ile | missense_variant | 3/3 | ENST00000442682.7 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
TMEM213 | ENST00000442682.7 | c.229G>A | p.Val77Ile | missense_variant | 3/3 | 1 | NM_001085429.2 | P4 | |
TMEM213 | ENST00000397602.7 | c.226G>A | p.Val76Ile | missense_variant | 3/3 | 1 | A2 | ||
TMEM213 | ENST00000458494.1 | c.157G>A | p.Val53Ile | missense_variant | 2/2 | 4 | |||
TMEM213 | ENST00000413208.1 | c.154+1576G>A | intron_variant | 3 |
Frequencies
GnomAD3 genomes AF: 0.00000657 AC: 1AN: 152214Hom.: 0 Cov.: 33
GnomAD4 exome AF: 0.00000548 AC: 8AN: 1460982Hom.: 0 Cov.: 31 AF XY: 0.00000275 AC XY: 2AN XY: 726824
GnomAD4 genome AF: 0.00000657 AC: 1AN: 152214Hom.: 0 Cov.: 33 AF XY: 0.00 AC XY: 0AN XY: 74372
ClinVar
Submissions by phenotype
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Dec 12, 2022 | The c.229G>A (p.V77I) alteration is located in exon 3 (coding exon 3) of the TMEM213 gene. This alteration results from a G to A substitution at nucleotide position 229, causing the valine (V) at amino acid position 77 to be replaced by an isoleucine (I). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at